136 related articles for article (PubMed ID: 12643941)
1. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
[TBL] [Abstract][Full Text] [Related]
2. A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.
Schlapbach A; Heng R; Di Padova F
Bioorg Med Chem Lett; 2004 Jan; 14(2):357-60. PubMed ID: 14698158
[TBL] [Abstract][Full Text] [Related]
3. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
5. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.
Regan J; Breitfelder S; Cirillo P; Gilmore T; Graham AG; Hickey E; Klaus B; Madwed J; Moriak M; Moss N; Pargellis C; Pav S; Proto A; Swinamer A; Tong L; Torcellini C
J Med Chem; 2002 Jul; 45(14):2994-3008. PubMed ID: 12086485
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
Dumas J; Hatoum-Mokdad H; Sibley RN; Smith RA; Scott WJ; Khire U; Lee W; Wood J; Wolanin D; Cooley J; Bankston D; Redman AM; Schoenleber R; Caringal Y; Gunn D; Romero R; Osterhout M; Paulsen H; Housley TJ; Wilhelm SM; Pirro J; Chien DS; Ranges GE; Shrikhande A; Muzsi A; Bortolon E; Wakefield J; Gianpaolo Ostravage C; Bhargava A; Chau T
Bioorg Med Chem Lett; 2002 Jun; 12(12):1559-62. PubMed ID: 12039561
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.
Stelmach JE; Liu L; Patel SB; Pivnichny JV; Scapin G; Singh S; Hop CE; Wang Z; Strauss JR; Cameron PM; Nichols EA; O'Keefe SJ; O'Neill EA; Schmatz DM; Schwartz CD; Thompson CM; Zaller DM; Doherty JB
Bioorg Med Chem Lett; 2003 Jan; 13(2):277-80. PubMed ID: 12482439
[TBL] [Abstract][Full Text] [Related]
9. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
[TBL] [Abstract][Full Text] [Related]
10. Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles.
Boehm JC; Bower MJ; Gallagher TF; Kassis S; Johnson SR; Adams JL
Bioorg Med Chem Lett; 2001 May; 11(9):1123-6. PubMed ID: 11354358
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies.
Liu M; Wang S; Clampit JE; Gum RJ; Haasch DL; Rondinone CM; Trevillyan JM; Abad-Zapatero C; Fry EH; Sham HL; Liu G
Bioorg Med Chem Lett; 2007 Feb; 17(3):668-72. PubMed ID: 17107797
[TBL] [Abstract][Full Text] [Related]
13. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
Redman AM; Johnson JS; Dally R; Swartz S; Wild H; Paulsen H; Caringal Y; Gunn D; Renick J; Osterhout M; Kingery-Wood J; Smith RA; Lee W; Dumas J; Wilhelm SM; Housley TJ; Bhargava A; Ranges GE; Shrikhande A; Young D; Bombara M; Scott WJ
Bioorg Med Chem Lett; 2001 Jan; 11(1):9-12. PubMed ID: 11140741
[TBL] [Abstract][Full Text] [Related]
14. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
[TBL] [Abstract][Full Text] [Related]
15. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
Honma T; Hayashi K; Aoyama T; Hashimoto N; Machida T; Fukasawa K; Iwama T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Iwasawa Y; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4615-27. PubMed ID: 11741479
[TBL] [Abstract][Full Text] [Related]
16. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.
Mavunkel BJ; Chakravarty S; Perumattam JJ; Luedtke GR; Liang X; Lim D; Xu YJ; Laney M; Liu DY; Schreiner GF; Lewicki JA; Dugar S
Bioorg Med Chem Lett; 2003 Sep; 13(18):3087-90. PubMed ID: 12941340
[TBL] [Abstract][Full Text] [Related]
17. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Jones PD; Tsai HJ; Do ZN; Morisseau C; Hammock BD
Bioorg Med Chem Lett; 2006 Oct; 16(19):5212-6. PubMed ID: 16870439
[TBL] [Abstract][Full Text] [Related]
19. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
Cirillo PF; Pargellis C; Regan J
Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
[TBL] [Abstract][Full Text] [Related]
20. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
